Stifel Downgrades Sage Therapeutics (SAGE) to Hold, 'we think Biogen is unlikely to buy Sage outright '

August 7, 2023 10:11 AM EDT Send to a Friend
(Updated - August 7, 2023 10:12 AM EDT)

Stifel analyst Paul Matteis downgraded Sage Therapeutics (NASDAQ: SAGE) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login